NFKB1 and urinary bladder carcinoma: In conclusion, regorafenib not only induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF‐κB‐modulated tumor progression in bladder cancer in vitro and in vivo (Figure 5).